All lobbying filings

AVENUE SOLUTIONS

Lobbying for MERCK & CO. INC. · developer, manufacturer and distributor of pharmaceuticals

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Apr 21, 2025

Official filing document

Bills named in this filing 5

S 891
Bipartisan Health Care Act
HR 1968
Full-Year Continuing Appropriations and Extensions Act, 2025
HR 1672
Maintaining Investments in New Innovation Act
HR 2484
Seniors’ Access to Critical Medications Act of 2025
HR 946
ORPHAN Cures Act

Lobbying activity 2

Health Issues

S. 891, Bipartisan Health Care Act; H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (PL 119-4); Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation

Medicare/Medicaid

Value of prescription drugs; Issues related to Medicare Parts B and D; Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation; Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 1672, Maintaining Investments in New Innovation Act; Biosimilars Access and Affordability Act; H.R. 2484, Seniors Access to Critical Medications Act; H.R. 946, ORPHAN Cures Act

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.